Investors

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into an option agreement with a multinational consumer goods company in relation to its cholesterol reducing product. The terms of the agreement provide the multinational (for a nominal payment) with an option to enter into a definitive agreement following the results of a trial.

The terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of our first agreement with a global partner for our cholesterol reducing product. We believe that OptiBiotix's strong science base together with our partners brand portfolio and global reach will help both companies improve the health and well being of people around the world."

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.